Outbreak of invasive Streptococcus pneumoniae serotype 12F among a marginalized inner-city population in Winnipeg, Canada, 2009-2011

Clinical Infectious Diseases

Volumn 59, Issue 5, 2014, Pages 651-657

  Schillberg, Erin ^a,f   Isaac, Michael ^b   Deng, Xianding ^c   Peirano, Gisele ^d,e   Wylie, John L ^b   Van Caeseele, Paul ^b   Pillai, Dylan R ^d,e   Sinnock, Hasantha ^b   Mahmud, Salaheddin M ^a,b  

^a WINNIPEG REGIONAL HEALTH AUTHORITY   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e CALGARY LABORATORY SERVICES   (Canada)

^f MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

Homeless; Invasive pneumococcal disease; Outbreak; Serotype 12F; Surveillance

Indexed keywords

ERYTHROMYCIN; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; PNEUMOCOCCUS VACCINE;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; CANADA; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTILOCUS VARIABLE NUMBER TANDEM REPEAT ANALYSIS; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RISK FACTOR; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; TANDEM REPEAT; ADOLESCENT; AGED; CHILD; CLASSIFICATION; DRUG DEPENDENCE; EPIDEMIC; GENETICS; HOMELESS PERSON; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; POVERTY; SEROTYPING; URBAN POPULATION; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CANADA; CHILD; DISEASE OUTBREAKS; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; HOMELESS PERSONS; HUMANS; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POVERTY; SEROGROUP; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; SUBSTANCE-RELATED DISORDERS; URBAN POPULATION; VACCINATION; YOUNG ADULT;

EID: 84907419452     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu366     Document Type: Article

References (39)

1. Centers for Disease Control and Prevention. Outbreak of invasive pneumococcal disease - Alaska, 2003-2004. MMWR Morb Mortal Wkly Rep 2005; 54:72-5.
2. Hoge CW, Reichler MR, Dominguez EA, et al. An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail. N Engl J Med 1994; 331:643-8. (Pubitemid 24276864)
3. Lee EH, Hosea S, Schulman E, et al. Streptococcus pneumoniae serotype 12F outbreak in a homeless population - California, 2004. In: 54th Annual Epidemic Intelligence Service (EIS) Conference, Atlanta, Georgia, April 11-15, 2005. Abstract p. 79.
4. Torzillo PJ, Morey F, Gratten M, Murphy D, Matters R, Dixon J. Changing epidemiology of invasive pneumococcal disease in central Australia prior to conjugate vaccine: a 16-year study. Vaccine 2007; 25:2375-8. (Pubitemid 46394513)
5. Romney MG, Hull MW, Gustafson R, et al. Large community outbreak of Streptococcus pneumoniae serotype 5 invasive infection in an impoverished, urban population. Clin Infect Dis 2008; 47:768-74.
6. Rakov AV, Ubukata K, Robinson DA. Population structure of hyperinvasive serotype 12F, clonal complex 218 Streptococcus pneumoniae revealed by multilocus boxB sequence typing. Infect Genet Evol 2011; 11:1929-39.
7. Antonio M, Dada-Adegbola H, Biney E, et al. Molecular epidemiology of pneumococci obtained from Gambian children aged 2-29 months with invasive pneumococcal disease during a trial of a 9-valent pneumococcal conjugate vaccine. BMC Infect Dis 2008; 8:81.
8. Skoczynska A, Sadowy E, Bojarska K, et al. The current status of invasive pneumococcal disease in Poland. Vaccine 2011; 29:2199-205.
9. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294:2043-51. (Pubitemid 41539937)
10. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46. (Pubitemid 36514704)
11. Manitoba Health. Invasive pneumococcal disease (Streptococcus pneumoniae) (pneumococcus), 2011. Available at: http://www.gov.mb.ca/health/publichealth/ cdc/protocol/strep.pdf. Accessed 10 June 2013.
12. Austrian R. The Quellung reaction, a neglected microbiologic technique. Mt Sinai J Med 1976; 43:699-709. (Pubitemid 8021485)
13. Lovgren M, Spika J, Talbot J. Invasive Streptococcus pneumoniae infections: serotype distribution and antimicrobial resistance in Canada, 1992-1995. Can Med Assoc J 1998; 158:327-31. (Pubitemid 28072654)
14. Manitoba Centre for Health Policy. Constructing the SEFI (1996) score, 2001. Available at: http://mchp-appserv.cpe.umanitoba.ca/concept/sefi-1996- additional.html. Accessed 10 June 2013.
15. Public Health Agency of Canada. Canadian immunization guide. 7th ed. 2006. Available at: www.phac-aspc.gc.ca/publicat/ccdr-rmtc/08vol34. Accessed 25 February 2014.
16. Louie M, Louie L, Papia G, Talbot J, Lovgren M, Simor A. Molecular analysis of the genetic variation among penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae serotypes in Canada. J Infect Dis 1999; 179:892-900. (Pubitemid 29159334)
17. Enright MC, Spratt BG. A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology 1998; 144:3049-60. (Pubitemid 28515583)
18. Koeck JL, Njanpop-Lafourcade BM, Cade S, et al. Evaluation and selection of tandem repeat loci for Streptococcus pneumoniae MLVA strain typing. BMC Microbiol 2005; 5:66.
19. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 23rd informational supplement. Wayne, PA: CLSI, 2013.
20. Shrestha S, Foxman B, Weinberger DM, Steiner C, Viboud C, Rohani P. Identifying the interaction between influenza and pneumococcal pneumonia using incidence data. Sci Transl Med 2013; 5:191ra84.
21. Mahmud SM, Becker M, Keynan Y, et al. Estimated cumulative incidence of pandemic (H1N1) influenza among pregnant women during the first wave of the 2009 pandemic. Can Med Assoc J 2010; 182:1522.
22. Chiba N, Morozumi M, Sunaoshi K, et al. Serotype and antibiotic resistance of isolates from patients with invasive pneumococcal disease in Japan. Epidemiol Infect 2010; 138:61-8.
23. Song JY, Nahm MH, Moseley MA. Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean Med Sci 2013; 28:4-15.
24. Deng X, Church D, Vanderkooi OG, Low DE, Pillai DR. Streptococcus pneumoniae infection: a Canadian perspective. Expert Rev Anti Infect Ther 2013; 11:781-91.
25. Wierzbowski AK, Karlowsky JA, Adam HJ, Nichol KA, Hoban DJ, Zhanel GG. Evolution and molecular characterization of macrolide-resistant Streptococcus pneumoniae in Canada between 1998 and 2008. J Antimicrob Chemother 2014; 69:59-66.
26. Klein JO. The epidemiology of pneumococcal disease in infants and children. Rev Infect Dis 1981; 3:246-53.
27. Lloyd-Evans N, O'Dempsey TJ, Baldeh I, et al. Nasopharyngeal carriage of pneumococci in Gambian children and in their families. Pediatr Infect Dis J 1996; 15:866-71. (Pubitemid 26339595)
28. Loda FA, Collier AM, Glezen WP, Strangert K, Clyde WA Jr, Denny FW. Occurrence of Diplococcus pneumoniae in the upper respiratory tract of children. J Pediatr 1975; 87(6 pt 2):1087-93.
29. Robinson DA, Turner JS, Facklam RR, et al. Molecular characterization of a globally distributed lineage of serotype 12F Streptococcus pneumoniae causing invasive disease. J Infect Dis 1999; 179:414-22. (Pubitemid 29086644)
30. Bigham M, Patrick DM, Bryce E, et al. Epidemiology, antibiotic susceptibility, and serotype distribution of Streptococcus pneumoniae associated with invasive pneumococcal disease in British Columbia: a call to strengthen public health pneumococcal immunization programs. Can J Infect Dis 2003; 14:261.
31. Adam HJ, Schurek KN, Nichol KA, et al. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrob Agents Chemother 2007; 51:198-207. (Pubitemid 46047707)
32. Mercat A, Nguyen J, Dautzenberg B. An outbreak of pneumococcal pneumonia in two men's shelters. Chest 1991; 99:5.
33. Chang A, Osterloh J, Thomas J. Levamisole: a dangerous new cocaine adulterant. Clin Pharmacol Ther 2010; 88:408-11.
34. Knowles L, Buxton JA, Skuridina N, et al. Levamisole tainted cocaine causing severe neutropenia in Alberta and British Columbia. Harm Reduct J 2009; 6:30.
35. Wiens MO, Son WK, Ross C, Hayden M, Carleton B. Cases: cocaine adulterant linked to neutropenia. CMAJ 2010; 182:57-9.
36. Larocque A, Hoffman RS. Levamisole in cocaine: unexpected news from an old acquaintance. Clin Toxicol (Phila) 2012; 50:231-41.
37. Ferucci ED, Templin DW, Lanier AP. Rheumatoid arthritis in American Indians and Alaska Natives: a review of the literature. Semin Arthritis Rheum 2005; 34:662-7. (Pubitemid 40193364)
38. Peschken CA, Esdaile JM. Rheumatic diseases in North America's indigenous peoples. Semin Arthritis Rheum 1999; 28:368-91. (Pubitemid 29289375)
39. Wylie JL, Shah L, Jolly A. Incorporating geographic settings into a social network analysis of injection drug use and bloodborne pathogen prevalence. Health Place 2007; 13:617-28. (Pubitemid 46498802)